Pharmafile Logo

MAKING THE FIRST YEAR MATTER

October 26, 2021 |  

*Mind+Matter closes its first year of business celebrating more than £4 million of new business wins in the UK *The global agency launched in Jan 21 has also been awarded a ‘Communique’ award for ‘Excelling in multi-channel campaigns’ for its work with CSL Behring, alongside six further award commendations and wins  *The agency offers a ‘health first, sector second’ approach with access to sector experts with unparalleled breadth and depth of capabilities *The growth has led to more than 60 new hires globally, and senior promotions to the UK leadership team alongside the launch of Gravity.ai – a first of its kind global healthcare intelligence data platform

Mind+Matter(an Ashfield Health company, part of UDG Healthcare), a ‘global creative powerhouse in health’ is celebrating its first year of business after securing more than £4 million in new business revenue across key strategic wins that span pharma, medical devices, consumer and animal health clients.

Since the launch of its new proposition in January 2021 following the merger of Pegasus, Ashfield Digital and Creative and Cambridge Biomarketing, the UK Mind+Matter team, led by Corrina Safeio, has gone from strength to strength, drawing on the expertise of its world-class experts based globally.

New senior roles include the promotion of Ian Rayfrom Associate Creative Director to Creative Director, and Kesha Tansey to Client Director. Ian and Kesha join the UK Mind+Matter leadership team and will pay a key role in shaping the future strategy and direction of the agency.

Safeio says it’s already very clear by the raft of new business wins that the health sector needs a deeply interconnected, cross-sector response to both existing clients and new client challenges.

“It’s been a phenomenal first year for Mind+Matter and I’m extremely proud of our talented team and what we have been able to accomplish together. Creating meaningful experiences by bringing data and emotion together to drive behaviour change is at the heart of what we do, day in day out. It’s this proposition alongside our health first, sector second approach that has chimed most with clients –existing and new.”

At the heart of the Mind+Matter offer is CHANGE, a behavioural science-led strategic methodology co-created with the internationally recognised Centre for Behaviour Change at University College London (itself an expert voice in the public health response to Covid-19).

In its first year, Mind+Matter also launched Gravity.ai a first of its kind global healthcare intelligence data platform. Gravity.ai incorporates artificial intelligence, predictive analytics, data modelling and scientific human consultancy to better understand audiences, behaviour and channel performance, ensuring clients get the best value for their investment.

Safeio adds: “Covid has shown how our individual health is also a truly global issue and personalised communications have never been more important. Matched with our deep earned, owned and paid expertise, Gravity.ai allows us to discover meaningful links between demographics, technologies, and customer behaviours and track the changing dynamics of HCP, patient and consumer communications in a rapidly shifting digital world. This powers our planning model CHANGE, along with proven behavioural science. It’s powerful stuff that delivers impactful, measurable results.”

Ben Beckley leads the new agency from Boston in the US, along with Managing Directors Corrina Safeio and Carina Whitridge, who head up the EMEA and US regions respectively.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

How will AI change field training?

Learn how a next-generation approach to field training – powered by GenAI and avatar simulations and enabled through Intelligent Commercialization™ – can transform field force effectiveness by delivering scalable, always-on,...

Inizio Ignite Sparks a New Era of Connected Advisory Solutions

Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.

MM+M Podcast explores AI-powered audience intelligence with Inizio Evoke

The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what...

Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series

Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

How DataGateway unified oncology data for real-world insights & market intelligence

Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.

Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.

Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.

ESMO 2025 highlights: How storytelling, design & emotion are transforming scientific engagement

Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders.

Preparing for ASH 2025: Pharma’s role in hematology innovation

As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...

AI without limits: A smarter, integrated approach to Medical Affairs

At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...